JP6818676B2 - インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 - Google Patents

インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 Download PDF

Info

Publication number
JP6818676B2
JP6818676B2 JP2017512462A JP2017512462A JP6818676B2 JP 6818676 B2 JP6818676 B2 JP 6818676B2 JP 2017512462 A JP2017512462 A JP 2017512462A JP 2017512462 A JP2017512462 A JP 2017512462A JP 6818676 B2 JP6818676 B2 JP 6818676B2
Authority
JP
Japan
Prior art keywords
inhibitors
inhibitor
nfκb
mek
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017512462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515910A (ja
JP2017515910A5 (enExample
Inventor
クリスティーナ エアハルト
クリスティーナ エアハルト
シュテファン ルートヴィヒ
シュテファン ルートヴィヒ
Original Assignee
アトリバ セラピューティクス ゲーエムベーハー
アトリバ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトリバ セラピューティクス ゲーエムベーハー, アトリバ セラピューティクス ゲーエムベーハー filed Critical アトリバ セラピューティクス ゲーエムベーハー
Publication of JP2017515910A publication Critical patent/JP2017515910A/ja
Publication of JP2017515910A5 publication Critical patent/JP2017515910A5/ja
Application granted granted Critical
Publication of JP6818676B2 publication Critical patent/JP6818676B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
JP2017512462A 2014-05-16 2015-05-18 インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 Expired - Fee Related JP6818676B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92455 2014-05-16
LU92455 2014-05-16
PCT/IB2015/053644 WO2015173788A1 (en) 2014-05-16 2015-05-18 Novel anti-infective strategy against influenza virus and s. aureus coinfections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020218254A Division JP2021059592A (ja) 2014-05-16 2020-12-28 インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略

Publications (3)

Publication Number Publication Date
JP2017515910A JP2017515910A (ja) 2017-06-15
JP2017515910A5 JP2017515910A5 (enExample) 2018-06-28
JP6818676B2 true JP6818676B2 (ja) 2021-01-20

Family

ID=50980349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512462A Expired - Fee Related JP6818676B2 (ja) 2014-05-16 2015-05-18 インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
JP2020218254A Pending JP2021059592A (ja) 2014-05-16 2020-12-28 インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020218254A Pending JP2021059592A (ja) 2014-05-16 2020-12-28 インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略

Country Status (10)

Country Link
US (3) US10456440B2 (enExample)
EP (2) EP3142658B1 (enExample)
JP (2) JP6818676B2 (enExample)
KR (1) KR102405136B1 (enExample)
CN (3) CN116942832A (enExample)
AU (3) AU2015260765B2 (enExample)
BR (1) BR112016026556A8 (enExample)
CA (1) CA2949004A1 (enExample)
EA (1) EA039897B1 (enExample)
WO (1) WO2015173788A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173788A1 (en) 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections
CA3016119A1 (en) * 2016-03-01 2017-09-08 Emerging Viral Therapeutics (HK) Limited Compositions and methods for treatment of influenza virus
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
KR20190064562A (ko) * 2016-07-08 2019-06-10 메타스타트, 아이앤씨. Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
ES2883639T3 (es) * 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
EP3873458A4 (en) * 2018-11-02 2022-07-06 University of Maryland, Baltimore TYPE 3 SECRETION SYSTEM INHIBITORS AND ANTIBIOTIC THERAPY
CN110063954B (zh) * 2019-04-10 2021-08-06 华中农业大学 Fhpi在制备治疗猫传染性腹膜炎药物中的应用
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN110292593A (zh) * 2019-08-05 2019-10-01 广州呼吸健康研究院 厚朴在制备抗流感药物上的应用
KR20220074869A (ko) 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
CN110859845B (zh) * 2019-12-10 2021-02-02 南京医科大学 丹参酮类化合物的应用
EP4085054B1 (en) * 2020-01-02 2025-02-19 Helmholtz-Zentrum für Infektionsforschung GmbH New pqsr inverse agonists
WO2021142144A1 (en) 2020-01-10 2021-07-15 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
MX2022013196A (es) * 2020-04-22 2022-11-14 Atriva Therapeutics Gmbh Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar.
KR102641463B1 (ko) * 2020-08-18 2024-02-27 한국생명공학연구원 바이러스 감염질환의 예방 또는 치료를 위한 화합물, 이를 포함하는 조성물 및 이의 용도
CN112552189A (zh) * 2020-11-10 2021-03-26 中国海洋大学 一种盐酸金刚烷胺与白藜芦醇的药物共晶及其制备方法
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
CN116159140B (zh) * 2021-11-25 2025-07-25 中国科学院上海免疫与感染研究所 Mapk通路抑制剂在抗病原体感染中的应用
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN115644134B (zh) * 2022-10-31 2025-10-10 中国人民解放军军事科学院军事医学研究院 一种布鲁氏菌-甲型流感病毒共感染小鼠模型及其构建方法和应用
KR20240087518A (ko) 2022-12-01 2024-06-19 서울여자대학교 산학협력단 카페산을 포함하는 식물바이러스 방제용 조성물 및 이를 이용한 식물바이러스 방제 방법
CN118490680B (zh) * 2023-06-20 2025-02-11 吉林省西点药业科技发展股份有限公司 瑞香素在制备治疗病毒性肺炎的药物中的应用
CN116531389B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合雷公藤红素的应用及药物组合物
CN117105810B (zh) * 2023-10-23 2024-02-09 中国农业大学 一种具有广谱抗菌活性的化合物及其抗菌组合物
CN119925338A (zh) * 2025-02-10 2025-05-06 广州医科大学附属妇女儿童医疗中心 Bay 11-7085在防治肺炎中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191111B1 (pl) 1997-04-24 2006-03-31 Ortho Mcneil Pharm Inc Podstawione imidazole, sposób ich wytwarzania, kompozycje zawierające podstawione imidazole oraz ich zastosowanie
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0994858A1 (en) 1997-06-30 2000-04-26 Ortho-McNeil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
CA2321559A1 (en) 1998-02-26 1999-09-02 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
BR9913654A (pt) 1998-08-28 2001-11-27 Scios Inc Inibidores de p-38alfa quinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
EP1353905B1 (en) 2000-11-20 2007-01-10 Scios Inc. Piperidine/piperazine-type inhibitors of p38 kinase
AU2002303132A1 (en) 2001-03-16 2002-10-03 Tyler Curiel Inhibition of toxoplasma gondii) replication by pyridinylimidazoles
US7345078B2 (en) * 2002-05-31 2008-03-18 The Board Of Trustees Of Michigan State University NF-κB inhibitors and uses thereof
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
EP2903649A1 (en) 2012-10-08 2015-08-12 Westfälische Wilhelms-Universität Münster Mek inhibitors in the treatment of virus diseases
WO2015173788A1 (en) 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections

Also Published As

Publication number Publication date
CN113398271A (zh) 2021-09-17
EP3708156A1 (en) 2020-09-16
AU2020256326B2 (en) 2022-12-08
EP3142658B1 (en) 2020-01-15
JP2017515910A (ja) 2017-06-15
AU2020256326A1 (en) 2020-11-12
US10456440B2 (en) 2019-10-29
EA201692303A1 (ru) 2017-03-31
AU2015260765B2 (en) 2020-08-13
US20200101130A1 (en) 2020-04-02
EP3142658A1 (en) 2017-03-22
US11135263B2 (en) 2021-10-05
WO2015173788A1 (en) 2015-11-19
BR112016026556A2 (pt) 2017-08-15
CN107073123A (zh) 2017-08-18
EA039897B1 (ru) 2022-03-24
AU2022268364A1 (en) 2022-12-15
CN116942832A (zh) 2023-10-27
KR102405136B1 (ko) 2022-06-07
US20170080045A1 (en) 2017-03-23
US20220096590A1 (en) 2022-03-31
BR112016026556A8 (pt) 2021-07-06
KR20170005110A (ko) 2017-01-11
CA2949004A1 (en) 2015-11-19
JP2021059592A (ja) 2021-04-15
AU2015260765A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
JP6818676B2 (ja) インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
Bewley et al. Differential effects of p38, MAPK, PI3K or Rho kinase inhibitors on bacterial phagocytosis and efferocytosis by macrophages in COPD
Liu et al. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine
JP7618276B2 (ja) ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤
JP6294889B2 (ja) ウイルス疾患の処置におけるｍｅｋ阻害物質
Schräder et al. The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression
Bindu et al. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory
Chen et al. Allicin inhibited Staphylococcus aureus-induced mastitis by reducing lipid raft stability via LxRα in mice
JP2022529343A (ja) ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤
Brooks et al. Endotoxin-induced activation of equine platelets: evidence for direct activation of p38 MAPK pathways and vasoactive mediator production
KR101642042B1 (ko) 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도
Luna et al. Senolytic treatment attenuates immune cell infiltration without improving IAV outcomes in aged mice
JP2016175866A (ja) Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
TWI536985B (zh) 抑制乳癌細胞骨轉移的方法及醫藥組合物
Al-Abed et al. The FGF inhibitor, SU5402, inhibited Sulf1 expression when placed in the interdigital mesoderm. Menu

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201228

R150 Certificate of patent or registration of utility model

Ref document number: 6818676

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees